Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina

Chahla et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433, NCT04701710

Jan 2021

Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated with ivermectin and iota-carrageenan, and 117 controls, showing significantly lower cases with treatment. There were no moderate/severe cases with treatment vs. 10 in the control group. There were 4 cases with treatment (all mild) vs. 25 for the control group.

Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.

Important missing comments or errors? Let us know.

Study covers iota-carrageenan and ivermectin.

risk of moderate/severe case, 95.2% lower, RR 0.05, p = 0.002, treatment 0 of 117 (0.0%), control 10 of 117 (8.5%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate/severe COVID-19.

risk of case, 84.0% lower, RR 0.16, p = 0.004, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), NNT 5.6, adjusted per study, odds ratio converted to relative risk, all cases.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Chahla et al., 11 Jan 2021, Randomized Controlled Trial, Argentina, peer-reviewed, 11 authors, study period 15 October, 2020 - 31 December, 2020, this trial uses multiple treatments in the treatment arm (combined with ivermectin) - results of individual treatments may vary, trial NCT04701710 (history).

This Paper Iota-carragee..All

Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina

tive effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Rossana E. Chahla, MD, PhD 1 Luis Medina Ruiz, MD 2 Eugenia S. Ortega, MSc 3 Marcelo F. Morales, RN 4 Francisco Barreiro, MD 5 Alexia George, MD 5 Cesar Mancilla, RN 4 Sylvia D' Amato, RN 4 Guillermo Barrenechea, MSc 3 Daniel G. Goroso, PhD

References

Abd-Elsalam, Noor, Badawi, Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study

Alam, Murshed, Gomes, Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in dhakaan observational study, Eur J Med Heal Sci

Ashburn, Thor, Drug repositioning: identifying and developing new uses for existing drugs, Nat Rev Drug Discov

Caly, Druce, Catton, Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect , the company' s public news and information, Antivir Res

Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antivir Res

Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: a pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine

Chaccour, Ruiz-Castillo, Richardson, The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate the potential of ivermectin to reduce covid-19 transmission in low risk, non-severe covid-19 patients in the first 48 hours after symptoms onset: a structured summary of a study protocol, Trials

Chahla, Prophylaxis covid-19 in health workers through intensive treatment with ivermectin and iotacarrageenan (Ivercar-Tuc), ClinicalTrials

Chong, Sullivan, New uses for old drugs, Nature

H Ector, Roberto, Psaltis, Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Investig

Hirsch, Hector, Covid 19 and ivermectin prevention and treatment update, J Infect Dis Trav Med

Kory, Meduri, Varon, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther

Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial, EClinicalMedicine

Liu, Fang, Reagan, In silico drug repositioning: what we need to know, Drug Discov Today

Shouman, Hegazy, Nafae, Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial, J Clin Diagn Res

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0